医学
激素
激素疗法
肝病
肝细胞癌
疾病
脂肪变性
生理学
雌激素
胆汁淤积
睾酮(贴片)
内科学
激素替代疗法(女性对男性)
生物信息学
多囊卵巢病
非酒精性脂肪肝
雄激素
内分泌学
慢性肝病
肝细胞腺瘤
激素疗法
胆汁酸
妊娠胆汁淤积症
作者
Nora Cazzagon,Martina Gambato,Maurizia Rossana Brunetto,Erica Villa,Patrizia Burra,A. Floreani
摘要
The liver is central to sex hormone metabolism, and sex hormones in turn modulate hepatic physiology and disease processes. Oestrogens are often protective, while androgens tend to worsen disease progression. The clinical implications of hormonal therapies in patients with liver disease remain an area of active investigation. To review current evidence on the interplay between sex hormones and liver disease, with a focus on the safety and impact of hormonal therapies, including contraception, hormone replacement therapy, assisted reproductive technology and gender-affirming treatments. Prolonged or high-dose oestrogen exposure, particularly via oral contraceptives, has been associated with intrahepatic cholestasis and hepatocellular adenoma (HCA), especially in predisposed individuals. In contrast, hormone replacement therapy in postmenopausal women is generally safe and may confer metabolic and hepatic benefits. Oestrogens appear to slow fibrosis progression and reduce hepatocellular carcinoma risk, whereas androgens can promote steatosis and HBV-related oncogenesis. Hormonal therapies are safe in most patients with compensated chronic liver disease but require caution in settings such as in polycystic liver disease, where oestrogens can accelerate cyst growth. Emerging data also indicate a role of sex hormones in autoimmune and cholestatic diseases, as well as in outcomes of assisted reproduction and gender-affirming therapy. Hormonal therapies are feasible in most liver disease contexts, but individualised assessment, awareness of genetic predisposition, and disease-specific risks are essential to optimise safety and therapeutic benefit.
科研通智能强力驱动
Strongly Powered by AbleSci AI